CA2709899C - Compositions pharmaceutiques renfermant au moins un principe actif proteinique protege des enzymes digestives - Google Patents

Compositions pharmaceutiques renfermant au moins un principe actif proteinique protege des enzymes digestives Download PDF

Info

Publication number
CA2709899C
CA2709899C CA2709899A CA2709899A CA2709899C CA 2709899 C CA2709899 C CA 2709899C CA 2709899 A CA2709899 A CA 2709899A CA 2709899 A CA2709899 A CA 2709899A CA 2709899 C CA2709899 C CA 2709899C
Authority
CA
Canada
Prior art keywords
active ingredient
liquid
composition according
buffer
insulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2709899A
Other languages
English (en)
French (fr)
Other versions
CA2709899A1 (fr
Inventor
Farid Bennis
Jean-Jacques Serrano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2709899A1 publication Critical patent/CA2709899A1/fr
Application granted granted Critical
Publication of CA2709899C publication Critical patent/CA2709899C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA2709899A 2007-12-19 2008-12-18 Compositions pharmaceutiques renfermant au moins un principe actif proteinique protege des enzymes digestives Active CA2709899C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0759971A FR2925333B1 (fr) 2007-12-19 2007-12-19 Compositions pharmaceutiques renfermant au moins un principe actif proteinique protege des enzymes digestives
FR0759971 2007-12-19
PCT/FR2008/052357 WO2009083686A1 (fr) 2007-12-19 2008-12-18 Compositions pharmaceutiques renfermant au moins un principe actif proteinique protege des enzymes digestives

Publications (2)

Publication Number Publication Date
CA2709899A1 CA2709899A1 (fr) 2009-07-09
CA2709899C true CA2709899C (fr) 2018-01-16

Family

ID=39671377

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2709899A Active CA2709899C (fr) 2007-12-19 2008-12-18 Compositions pharmaceutiques renfermant au moins un principe actif proteinique protege des enzymes digestives

Country Status (18)

Country Link
US (1) US8309123B2 (enExample)
EP (1) EP2234598B1 (enExample)
JP (1) JP5676272B2 (enExample)
KR (2) KR20150132887A (enExample)
CN (1) CN101917967B (enExample)
AP (1) AP3573A (enExample)
AR (1) AR069847A1 (enExample)
AU (1) AU2008345474B2 (enExample)
BR (1) BRPI0821373B8 (enExample)
CA (1) CA2709899C (enExample)
EA (1) EA023107B1 (enExample)
FR (1) FR2925333B1 (enExample)
IL (1) IL206364A (enExample)
MA (1) MA31927B1 (enExample)
MX (1) MX2010006927A (enExample)
TN (1) TN2010000290A1 (enExample)
TW (1) TWI461226B (enExample)
WO (1) WO2009083686A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120035103A1 (en) * 2010-01-29 2012-02-09 Pillion Dennis J Method for administration of insulin and pharmaceutical composition thereof
RU2016147009A (ru) 2014-05-01 2018-06-04 Сан Фармасьютикал Индастриз Лимитед Композиции с пролонгированным высвобождением в виде суспензии
US10258583B2 (en) 2014-05-01 2019-04-16 Sun Pharmaceutical Industries Limited Extended release liquid compositions of guanfacine
US20180104197A9 (en) 2014-05-01 2018-04-19 Sun Pharmaceutical Industries Limited Extended release liquid compositions of metformin
US9962336B2 (en) 2014-05-01 2018-05-08 Sun Pharmaceutical Industries Limited Extended release suspension compositions
CA2956902A1 (en) 2014-07-30 2016-02-04 Sun Pharmaceutical Industries Limited Dual-chamber pack
WO2016071756A1 (en) * 2014-11-04 2016-05-12 Innopharmax, Inc. Oral administration of unstable or poorly-absorbed drugs
US10369078B2 (en) 2016-05-02 2019-08-06 Sun Pharmaceutical Industries Limited Dual-chamber pack for pharmaceutical compositions
US10238803B2 (en) 2016-05-02 2019-03-26 Sun Pharmaceutical Industries Limited Drug delivery device for pharmaceutical compositions
FR3120189B1 (fr) * 2021-03-01 2024-11-29 Farid Bennis Composition pharmaceutique pour une administration par voie orale d’un agoniste du récepteur du GLP-1

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE36225B1 (en) 1971-01-28 1976-09-15 Nat Res Dev Improvements relating to insulin derivatives
US4692433A (en) * 1983-10-12 1987-09-08 The Regents Of The University Of California Method and composition for regulating serum calcium levels of mammals
WO1985005029A1 (en) 1984-05-09 1985-11-21 Medaphore Inc. Oral insulin and a method of making the same
US4693433A (en) * 1986-06-06 1987-09-15 Merrill David Martin Unwind stand for web rolls
US6191105B1 (en) * 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
GB9417524D0 (en) * 1994-08-31 1994-10-19 Cortecs Ltd Pharmaceutical compositions
EP0781142A4 (en) * 1994-09-01 2003-04-09 Allied Medical Res Associates Compositions and methods for delivery of polypeptides
US5824638A (en) 1995-05-22 1998-10-20 Shire Laboratories, Inc. Oral insulin delivery
US5912014A (en) * 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US5783556A (en) * 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
US6071539A (en) * 1996-09-20 2000-06-06 Ethypharm, Sa Effervescent granules and methods for their preparation
CA2306024C (en) * 1997-10-01 2011-04-26 Flemington Pharmaceutical Corporation Buccal, polar and non-polar spray or capsule
SE9801495D0 (sv) * 1998-04-28 1998-04-28 Astra Ab Protein formulationa
US6531648B1 (en) * 1998-12-17 2003-03-11 Syngenta Participations Ag Grain processing method and transgenic plants useful therein
PT1031347E (pt) * 1999-01-27 2002-09-30 Idea Ag Transporte/imunizacao transnasal com veiculos muitissimo adaptaveis
SE9904121D0 (sv) * 1999-11-15 1999-11-15 Gustaf Jederstroem Hydrophobe biomolecular structure
US6531112B2 (en) * 2000-05-15 2003-03-11 Delrx Pharmaceutical Corporation Formulations for administering calcitonin and processes for preparing the same
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US7316819B2 (en) * 2001-03-08 2008-01-08 Unigene Laboratories, Inc. Oral peptide pharmaceutical dosage form and method of production
CN1335182A (zh) * 2001-08-08 2002-02-13 华中科技大学 胰岛素口腔喷剂及其制备工艺
GB0119859D0 (en) * 2001-08-15 2001-10-10 Qinetiq Ltd Eye tracking system
US20060258561A1 (en) * 2003-03-13 2006-11-16 Novo Nordisk A/S Novel NPH insulin preparations
KR100638041B1 (ko) * 2003-12-24 2006-10-23 주식회사 삼양사 수용성 약물의 경구투여용 나노입자 조성물 및 그의제조방법
EP1765406A4 (en) * 2004-05-21 2012-11-28 Mediplex Corp ADDITIVES FOR IMPROVED MUCOSAL ABSORPTION OF THERAPEUTIC AGENTS
WO2006014673A2 (en) * 2004-07-19 2006-02-09 Nobex Corporation Insulin-oligomer conjugates, formulations and uses thereof
AU2005271526B2 (en) * 2004-08-03 2011-12-08 Emisphere Technologies, Inc. Antidiabetic oral insulin-biguanide combination
AU2006249480A1 (en) 2005-05-23 2006-11-30 Sdg, Inc. Lipid construct for delivery of insulin to a mammal
US20090098205A1 (en) * 2005-09-15 2009-04-16 Council Of Scientife & Industrial Research pH SENSITIVE NANOPARTICLE FORMULATION FOR ORAL DELIVERY OF PROTEINS/PEPTIDES
EP1957113A4 (en) * 2005-11-21 2011-11-09 Medivas Llc POLYMER PARTICLES FOR THE OUTPUT OF MACROMOLECULES AND METHOD OF APPLICATION THEREFOR
US8927015B2 (en) * 2006-04-12 2015-01-06 Emisphere Technologies, Inc. Formulations for delivering insulin

Also Published As

Publication number Publication date
MA31927B1 (fr) 2010-12-01
BRPI0821373B1 (pt) 2020-04-22
AP3573A (en) 2016-02-08
WO2009083686A9 (fr) 2009-10-15
US8309123B2 (en) 2012-11-13
HK1146386A1 (en) 2011-06-03
CA2709899A1 (fr) 2009-07-09
CN101917967B (zh) 2013-05-22
AU2008345474A1 (en) 2009-07-09
BRPI0821373B8 (pt) 2021-05-25
KR20150132887A (ko) 2015-11-26
KR101592609B1 (ko) 2016-02-05
MX2010006927A (es) 2010-12-06
EP2234598B1 (fr) 2025-11-19
FR2925333A1 (fr) 2009-06-26
AR069847A1 (es) 2010-02-24
AU2008345474B2 (en) 2014-07-31
EA201070746A1 (ru) 2011-02-28
JP2011506587A (ja) 2011-03-03
BRPI0821373A2 (pt) 2015-06-16
TW200940107A (en) 2009-10-01
TWI461226B (zh) 2014-11-21
IL206364A (en) 2016-12-29
TN2010000290A1 (fr) 2011-11-11
EP2234598A1 (fr) 2010-10-06
WO2009083686A1 (fr) 2009-07-09
IL206364A0 (en) 2010-12-30
JP5676272B2 (ja) 2015-02-25
CN101917967A (zh) 2010-12-15
AP2010005298A0 (en) 2010-06-30
US20090176691A1 (en) 2009-07-09
KR20100095449A (ko) 2010-08-30
FR2925333B1 (fr) 2012-04-13
EA023107B1 (ru) 2016-04-29

Similar Documents

Publication Publication Date Title
CA2709899C (fr) Compositions pharmaceutiques renfermant au moins un principe actif proteinique protege des enzymes digestives
TW416854B (en) Buccal delivery of glucagon-like insulinotropic peptides
US20230302092A1 (en) Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
KR101719008B1 (ko) 약물 투여용 조성물
WO2009048945A1 (en) Rapid mucosal gel or film insulin compositions
WO2004104018A2 (en) Compositions for delivering peptide yy and pyy agonists
WO2011141685A2 (fr) Compositions nasales a visee systemique a base de cocoyl proline ou d'au moins un de ses constituants
US20240041983A1 (en) Improved pharmaceutical formulations of glp-1 receptor agonists
US20120040970A1 (en) Intranasal delivery system for dantrolene
CN115427065A (zh) Glp-1r和gcgr激动剂、制剂和使用方法
FR2623090A1 (fr) Compositions pharmaceutiques contenant une calcitonine
AU2022269659B2 (en) Erodible tablet
US20240277815A1 (en) Therapeutic Regimens and Methods for Treatment of Cardiovascular Risk Factors using a GLP-1R and GCGR Agonist
US20130090288A1 (en) Pharmaceutical compositions containing at least one protein active ingredient protected from digestive enzymes
WO2025166413A1 (en) Compositions and methods for delivering glp-1 agonists (metabolix)
EP4611792A1 (en) Therapeutic regimens and methods for treatment of cardiovascular risk factors using a glp-1r and gcgr agonist
HK1146386B (en) Pharmaceutical compositions containing at least one proteinaceous active ingredient protected against digestive enzymes
EP4301399A1 (fr) Composition pharmaceutique pour une administration par voie orale d'un agoniste du recepteur du glp-1
MXPA98003137A (en) Mouth-release of insulinotropic peptides like gluca
JPH0692846A (ja) アルコール摂取量減少剤

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130926